Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5780440 | 0.91 | MCHR2 (0.35) | MCHR2AKT1SIGMAR1CA1CA2 | |
| SCHEMBL6399852 | 0.80 | ALDH1A1 (0.41) | MCHR2OPRM1OPRK1CA1CA2 | |
| SCHEMBL5738672 | 0.76 | CA1 (0.55) | CA1CA2CA12CA7CA14 | |
| SCHEMBL5738668 | 0.76 | CA1 (0.55) | CA1CA2CA12CA7CA14 | |
| SCHEMBL5738892 | 0.76 | CA1 (0.55) | CA1CA2CA12CA7CA14 | |
| SCHEMBL5751441 | 0.75 | MTNR1A (0.46) | MCHR2MTNR1AMTNR1BLMNABLM | |
| SCHEMBL11295469 | 0.75 | MTNR1A (0.53) | CA1CA2MTNR1AMTNR1B | |
| SCHEMBL11312993 | 0.74 | MEN1 (0.41) | MTNR1AMTNR1BMEN1KMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL11316278 | 0.73 | MEN1 (0.40) | MTNR1AMTNR1BMEN1KMT2AKDM4E | |
| SCHEMBL6400837 | 0.73 | ALDH1A1 (0.40) | CA1CA2CA12CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288376-A1 | Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides | SMITHKLINE BEECHAM PLC | 2005-12-29 | — | — | US | disclosed |
| US-20050282819-A1 | Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia | GRAHAM JAMES M | 2005-12-22 | — | — | US | disclosed |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282819-A1 | Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia | CHRM1, CHRM2, CHRM5 | MCHR2 381/4885AKT1 1802/4885SIGMAR1 116/4885 |
| US-20050288376-A1 | Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides | CD22, CD2, NEU3 | MCHR2 2966/4885AKT1 3298/4885SIGMAR1 914/4885 |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | CD22, CD2, NEU3 | MCHR2 3235/4885AKT1 3480/4885SIGMAR1 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.